CRISPR Therapeutics AG has announced updates on its investigational allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel; formerly CTX112™), which targets CD19 and is being developed for the treatment of autoimmune diseases and hematologic malignancies. Preliminary data from ongoing studies in rheumatologic autoimmune diseases have shown deep B-cell depletion sustained for at least 28 days and initial clinical improvement, including the first systemic lupus erythematosus $(SLE)$ patient achieving remission through six months. No Grade 3 ICANS or CRS has been observed at the 100 million cell dose currently under investigation. An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura $(ITP)$ and warm autoimmune hemolytic anemia (wAIHA). In hematologic malignancies, a Phase 1/2 trial in relapsed/refractory B-cell malignancies is ongoing. Further clinical updates are expected to be provided in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615791) on December 22, 2025, and is solely responsible for the information contained therein.
Comments